(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

For reference, Seeking Alpha's Quant system is driven by powerful computer processing and SA's special 'Quantamental' ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The 36-year-old Officer Didarul Islam was among those killed. The shooter’s motive is not yet clear. Here’s the latest.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.